Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Aclarion Inc

Healthcare US ACON

3.49USD
-0.01(0.29%)

Last update at 2026-06-03T20:00:00Z

Day Range

3.383.49
LowHigh

52 Week Range

2.3412.03
LowHigh

Fundamentals

  • Previous Close 3.50
  • Market Cap8.06M
  • Volume55508
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-6.82498M
  • Revenue TTM0.08M
  • Revenue Per Share TTM0.14
  • Gross Profit TTM 0.00683M
  • Diluted EPS TTM-13.61

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -7.23363M -6.99293M -4.91137M -7.60554M -4.95029M
Minority interest - - - - -
Net income -7.23363M -6.99293M -4.91137M -9.11177M -3.53459M
Selling general administrative 4124832.00M 3.61M 3.25M 4.47M 1.83M
Selling and marketing expenses 1900598.00M 0.98M 0.76M 0.54M 0.33M
Gross profit -0.22058M -0.08404M -0.00032M -0.00485M -0.00888M
Reconciled depreciation 0.23M 0.19M 0.16M 0.19M 0.19M
Ebit -7.05239M -6.45746M -4.30309M -6.09852M -2.95304M
Ebitda -6.82498M -6.26432M -4.14041M -5.90318M -4.65664M
Depreciation and amortization 0.23M 0.19M 0.16M 0.20M -1.70360M
Non operating income net other - - - - -
Operating income -7.05239M -5.51305M -4.87598M -6.09852M -2.95304M
Other operating expenses 7.13M 5.56M 4.95M 6.16M 3.01M
Interest expense 0.00000M 0.54M 0.61M 1.51M 0.48M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.41M 0.00032M 0.00017M 0.00251M -
Net interest income 0.41M -0.53515M -0.60812M -1.50504M -0.47648M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 0.00000M -0.00000M 1.51M -1.41569M
Total revenue 0.08M 0.05M 0.08M 0.06M 0.06M
Total operating expenses 6.83M 5.43M 4.88M 6.09M 2.94M
Cost of revenue 0.30M 0.13M 0.08M 0.07M 0.07M
Total other income expense net -0.18124M -1.47988M -0.03539M -1.50703M -1.99725M
Discontinued operations - - - - -
Net income from continuing ops -7.23363M -6.99293M -4.91137M -7.60554M -4.95029M
Net income applicable to common shares - - - -7.48412M -5.95589M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 13672404.00M 2.12M 2.46M 3.21M 1.89M
Intangible assets 1251531.00M 1.29M 1.17M 1.21M 1.14M
Earning assets - - - - -
Other current assets 380914.97M 0.35M 0.14M 0.20M 0.27M
Total liab 837287.00M 1.15M 3.19M 1.42M 7.62M
Total stockholder equity 12835117.00M 0.97M -0.72799M 1.79M -5.72932M
Deferred long term liab - - - - -
Other current liab 837286.67M 0.62M 1.30M 0.96M 4.56M
Common stock 9.00M - 0.00001M 0.00008M 0.00007M
Capital stock 0.00001M 0.00000M 0.00001M 0.00008M 0.00031M
Retained earnings -58495940.00000M -51.26231M -44.28153M -39.90710M -31.88604M
Other liab - - - - -
Good will - - - - -
Other assets - - 0.00000M 0.00000M -
Cash 12015789.00M 0.45M 1.03M 1.47M 0.45M
Cash and equivalents - - - - -
Total current liabilities 837287.00M 1.15M 3.19M 1.42M 7.62M
Current deferred revenue - - - - -
Net debt -12015789.00000M -0.45366M 0.09M -1.47281M 1.55M
Short term debt - - 1.13M - 2.00M
Short long term debt - - 1.13M - 2.00M
Short long term debt total - - 1.13M - 2.00M
Other stockholder equity 71331119.33M 52.23M 43.55M 41.69M 26.16M
Property plant equipment - - - 0.00335M 0.01M
Total current assets 12396704.00M 0.82M 1.19M 1.99M 0.73M
Long term investments - - - - -
Net tangible assets - - - 1.02M -13.97642M
Short term investments - 0.04M - - -
Net receivables 0.03M 0.02M 0.01M 0.02M 0.00628M
Long term debt - - - - -
Inventory - - 0.00000M 0.30M -
Accounts payable 0.33M 0.53M 0.76M 0.46M 1.06M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - 0.10M - -
Deferred long term asset charges - - - - -
Non current assets total 1275700.00M 1.30M 1.27M 1.22M 1.16M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.32194M -0.11952M -0.20787M -0.15201M
Change to liabilities - - - -0.60310M 0.20M
Total cashflows from investing activities -203902.00000M -0.32194M -0.11952M -0.20787M -0.15201M
Net borrowings 0.00000M -0.30097M 2.25M -2.00000M 2.94M
Total cash from financing activities 18945234.00M 5.03M 3.31M 6.55M 2.94M
Change to operating activities - - - -0.00070M 0.46M
Net income -7233629.00000M -6.99293M -4.91137M -7.60554M -4.95029M
Change in cash 11577128.00M -0.56741M -0.45174M 1.03M 0.44M
Begin period cash flow 463661.00M 1.03M 1.48M 0.45M 0.01M
End period cash flow 12040789.00M 0.46M 1.03M 1.48M 0.45M
Total cash from operating activities -7164204.00000M -5.27161M -3.64695M -5.31417M -2.34995M
Issuance of capital stock 20.26M 6.57M 1.46M 8.55M -
Depreciation 227406.00M 0.19M 0.16M 0.19M 0.19M
Other cashflows from investing activities -203901.79610M -0.32194M -0.11952M - -
Dividends paid 5425.00M 0.06M - 0.42M -
Change to inventory - - - - -
Change to account receivables -0.01135M 0.00727M -0.00149M -0.01229M 0.02M
Sale purchase of stock -1.21359M 0.00000M -0.00100M - -
Other cashflows from financing activities 18950640.05M -0.24596M -0.39822M 0.42M -0.15201M
Change to netincome - - - 2.59M 1.73M
Capital expenditures 0.02M 0.32M 0.12M 0.21M 0.15M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.35790M -0.56424M 0.62M 0.81M 0.68M
Stock based compensation 105368.00M 0.29M 0.46M 1.29M 0.18M
Other non cash items -263348.64210M 1.80M 0.02M 0.00379M 1.90M
Free cash flow -7164204.00000M -5.59355M -3.76647M -5.52304M -2.50195M

Peer Comparison

Sector: Healthcare Industry: Health Information Services

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ACON
Aclarion Inc		 -0.01 0.29% 3.49 - - 106.39 0.63 101.77 -0.5627
VEEV
Veeva Systems Inc Class A		 -4.22 2.31% 178.72 54.61 33.22 12.83 6.73 11.14 58.84
MTHRF
M3 Inc		 - -% 8.55 29.72 25.00 0.05 4.38 0.04 0.12
MTHRY
M3 Inc		 -0.064 1.34% 4.71 31.84 26.25 0.05 4.60 0.04 0.12
BTSG
BrightSpring Health Services, Inc. Common Stock		 1.54 2.60% 60.88 100.22 40.65 0.69 4.92 0.92 25.80

Reports Covered

Stock Research & News

View All

Profile

Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

Aclarion Inc

8181 Arista Place, Broomfield, CO, United States, 80021

Key Executives

Name Title Year Born
Dr. Jeffrey John Thramann M.D. Exec. Chairman 1965
Mr. Brent Ness CEO, Pres & Director 1967
Mr. John Lorbiecki Chief Financial Officer 1964
Mr. Ryan Bond Chief Strategy Officer 1975
Dr. Jeffrey John Thramann M.D. Executive Chairman 1965
Mr. Ryan Bond Chief Strategy Officer 1973
Mr. Brent Ness CEO, President & Director 1967
Mr. John Lorbiecki Chief Financial Officer 1963
Mr. Ryan Bond Chief Strategy Officer 1972
Dr. Jeffrey John Thramann M.D. Executive Chairman 1966

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.